E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies
Gautam Borthakur,James M. Foran,Tapan M. Kadia,Elias Jabbour,Paul Wissel,Donna S. Cox,Yanmei Xu,John W. Bauman,Melanie Baccus,Jeanne Connor,Jorge E. Cortes,Hagop M. Kantarjian +11 more
TL;DR: GSK1120212 administered at 2mg/day orally was tolerable in subjects with relapsed or refractory AML and other leukemias and showed preliminary anti-leukemic clinical activity, and a phase II study in AML, MDS and CMML has been initiated.
Journal ArticleDOI
Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
Nicholas J. Short,Hagop M. Kantarjian,Nitin Jain,Xuelin Huang,Guillermo Montalban-Bravo,Tapan M. Kadia,Naval Daver,Kelly S. Chien,Yesid Alvarado,Guillermo Garcia-Manero,Ghayas C Issa,W. Macaron,F. Haddad,Monica Kwari,Ricardo Delumpa,E. Mayor,Wu Deen,Jennifer Thankachan,Christopher R. Loiselle,J. Rivera,Anna Milton,Lourdes Waller,Glenda Banks,Rebecca Garris,Marina Konopleva,Farhad Ravandi,Elias Jabbour +26 more
TL;DR: Ponatinib and blinatumomab both have single-agent activity in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and may reduce the need for allogeneic stem cell transplantation (SCT) in first remission as discussed by the authors .
Journal ArticleDOI
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors
Akash Mukherjee,Denái R. Milton,Elias Jabbour,Alison M. Gulbis,Tapan M. Kadia,Nitin Jain,Celina Ledesma,Jan A. Burger,Alessandra Ferrajoli,William G. Wierda,L. Jeffrey Medeiros,Hagop M. Kantarjian,Richard E. Champlin,Issa F. Khouri +13 more
TL;DR: It is concluded that a prior use of SMI does not impair the outcomes after alloSCT, and the risks of graft-versus-host disease, non-relapse mortality and survival outcomes of allogeneic stem cell transplantation in patients with chronic lymphocytic leukemia, Richter's syndrome, or lymphoma after small molecule inhibitors (SMIs).
Journal ArticleDOI
Decitabine in myelodysplastic syndromes
TL;DR: Combination therapies that augment decitabine’s epigenetic effect, or take advantage of gene activation, will likely improve clinical responses and may extend its use to the treatment of other malignancies.
Journal ArticleDOI
Emerging drugs for acute lymphocytic leukemia
TL;DR: Patients with acute lymphoblastic leukemia will receive treatment plans that are more individualized than previously possible, as the genetic and molecular characterization of ALL is more completely understood.